Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.
Tracking how individual lung cancer lesions evolve separately over time could help doctors decide when to target specific tumors with radiation or surgery rather than systemic therapy alone.
This JCO perspective from MSK/international consortium introduces the concept of metastatic trajectories in NSCLC — characterizing intrapatient lesion heterogeneity over time to inform adaptive therapy — proposing standardized reporting parameters and identifying ctDNA/radiomics as candidate predictive biomarkers. The framework could rationalize local consolidative therapy decisions and forms a foundation for next-generation NSCLC clinical trials.
What the study was
- Study design
- Conceptual framework review with evidence synthesis
- Population
- Metastatic NSCLC patients
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Journal of Clinical Oncology
Why it surfaced
High-impact JCO conceptual paper from MSK+international group; metastatic trajectory framework novel and could reshape NSCLC trial design; strong authorship; limited by being a framework not primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.